Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MODIFYPD

Financiado

Cerrado

Effects of posttranslational modifications of alpha synuclein on dopaminergic ne...

Effects of posttranslational modifications of alpha synuclein on dopaminergic neurodegeneration in a novel viral vector mediated in vivo model of Parkinson s disease One of the major pathological hallmarks of Parkinson´s disease (PD) is the progressive loss of specific dopaminergic projection neurons, especially those located in the substantia nigra pars compacta. The neurodegeneration is acco... ver más

31/10/2012

180K€

Presupuesto del proyecto: 180K€

Líder del proyecto

MAX IV Laboratory, Lund University No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-10-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

179.67K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NEURASYNC Academic Industrial Training Network on Alpha Synuclein rela... 2M€ Cerrado

Alpha-Synuclein Blocking the prion like disease propagation in Parkinson s d... 200K€ Cerrado

oxDOPAMINE Unraveling the mystery of preferential degeneration of midbr... 2M€ Cerrado

BFU2012-39737 MECANISMOS DE NEURODEGENERACION DEPENDIENTES DE ALFA-SINUCLE... 35K€ Cerrado

BIO2017-91475-EXP PEPTIDOS HELICOIDALES PARA CURAR LA ENFERMEDAD DE PARKINSON 30K€ Cerrado

PID2020-120380RB-I00 USO DE VECTORES VIRALES ADENO-ASOCIADOS PARA EL DISEÑO Y VAL... 158K€ Cerrado

Líder del proyecto

MAX IV Laboratory, Lund University No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 180K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto One of the major pathological hallmarks of Parkinson´s disease (PD) is the progressive loss of specific dopaminergic projection neurons, especially those located in the substantia nigra pars compacta. The neurodegeneration is accompanied by the presence of cytoplasmic inclusions called Lewy bodies, which invariably contain the α-synuclein (α-syn) protein as a major component. Aggregation of α-syn in the brains of PD patients has attracted much attention also because point mutations in the α-syn gene were found to cause rare dominantly inherited form of PD. Although the precise mechanism of the selective vulnerability of dopaminergic neurons in the midbrain remains unknown, there is increasing evidence that multiple pathogenic factors including impaired handling of cytoplasmic dopamine (DA), elevated levels of reactive oxygen species (ROS) and abnormal phosphorylation of α-syn could cause selective death of these cells via the accumulation of soluble neurotoxic α-syn species. Building on the know how and expertise of the host lab I propose to study 1) the pathogenic interaction of DA/α-syn by genetically increasing cytoplasmic DA levels in the viral vector mediated α-syn overexpression model, which I propose would result in a more pronounced neurodegeneration; 2) the role of ROS by upregulation of the enzyme methionine sulfoxide reductase A (known to prevent oxidative damage by scavenging of ROS). I hypothesize that expression of this enzyme should result in protection of dopaminergic neurons in the α-syn overexpression model; and 3) the consequences of increased Ser 129 phosphorylation of α-syn by overexpressed polo like kinases, which should modify neurotoxicity in the viral vector mediated α-syn overexpression model. These 3 approaches could give important clues for understanding the mechanisms underlying the selective neurodegeneration in PD and thus lead to the development of novel therapeutic strategies in PD.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores